Avalyn Pharma Inc.
Nasdaq · CIK 0001540171 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-27.9M
Net Income
$-26.9M
Eps Basic
-21.83
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-27.9M | - | - |
| Net Income | $-26.9M | - | - |
| Eps Basic | -21.83 | - | - |
| Eps Diluted | -21.83 | - | - |
| Cash And Equivalents | $92.3M | - | - |
| Total Assets | $135.7M | - | - |
| Total Liabilities | $27.7M | - | - |
| Shareholders Equity | $-264.2M | - | - |
| Operating Cash Flow | $-29.9M | - | - |
| Capital Expenditures | $318,000 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Avalyn Pharma Inc. | 2026-06-03 | 0001193125-26-254623 |
| 4 | Avalyn Pharma Inc. | 2026-05-05 | 0001388325-26-000021 |
| 4 | Avalyn Pharma Inc. | 2026-05-05 | 0001193125-26-205201 |
| 4 | Avalyn Pharma Inc. | 2026-05-01 | 0001193125-26-201894 |
| 4 | Avalyn Pharma Inc. | 2026-05-01 | 0001193125-26-201887 |
| 4 | Avalyn Pharma Inc. | 2026-05-01 | 0001193125-26-201863 |